|Bid||3.5000 x 800|
|Ask||3.6000 x 800|
|Day's range||3.3500 - 3.5900|
|52-week range||2.4900 - 12.8200|
|Beta (5Y monthly)||1.69|
|PE ratio (TTM)||N/A|
|Earnings date||20 Dec 2022 - 26 Dec 2022|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||28 Aug 1996|
|1y target est||15.00|
VIENNA, Va., September 12, 2022--CEL-SCI Corporation (NYSE American: CVM) today announced two poster presentations were delivered at the European Society for Medical Oncology (EMSO) annual Congress on September 10, 2022 in Paris, France. Data presented were from the Company's pivotal Phase 3 study, the largest study ever conducted in newly diagnosed locally advanced squamous cell carcinoma of the head and neck.
VIENNA, Va., September 07, 2022--CEL-SCI Corporation issues letter to shareholders.
VIENNA, Va., August 19, 2022--CEL-SCI corporation announces Phase 3 Multikine head and neck cancer results posted on clinicaltrials.gov.